DRG Market Assessment reports
Access comprehensive market intelligence covering Disease Landscape & Forecast, Epidemiology Intelligence, Biosimilars Intelligence, China In-depth and more.
Colorectal Cancer – Unmet Need – Unmet Need – Previously treated BRAF-mutant or RAS-mutant metastatic colorectal cancer (US/EU)
The treatment landscape for second- and later-line metastatic colorectal cancer with BRAF or RAS mutations is rapidly changing following the market entry of biomarker-specific combination therapies…
Axial Spondyloarthritis – Unmet Need – Unmet Need – Nonradiographic Axial Spondyloarthritis (US/EU)
TNF-alpha inhibitors, such as AbbVie’s Humira, Amgen’s Enbrel, Johnson & Johnson Innovative Medicine’s Simponi, and UCB’s Cimzia, are approved for the treatment of nonradiographic axial…
Non-Small-Cell Lung Cancer | Current Treatment: Physician Insights | US | May 2025
Immune checkpoint inhibitors continue to dominate the treatment of non-small-cell lung cancer (NSCLC), while biomarker-based approaches are driving increasing patient segmentation. In 2024, Imfinzi…
Small Cell Lung Cancer – Current Treatment – Current Treatment: Physician Insights – Small-Cell Lung Cancer (US)
The small-cell lung cancer (SCLC) treatment landscape is dominated by chemotherapy and chemoradiotherapy. The immune checkpoint inhibitors Tecentriq (Roche; FDA approved in 2019) and Imfinzi (…
Small Cell Lung Cancer – Current Treatment – Treatment Sequencing – Small-Cell Lung Cancer (US)
KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand who to position…
Multiple Myeloma – Unmet Need – Unmet Need – Third- and Fourth-Line Multiple Myeloma (US/EU)
The treatment of multiple myeloma is complex, often involving combinations of CD38-blocking monoclonal antibodies (MAbs), immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), chemotherapy,…
